Lessons from a damaging genetics therapy test for Duchenne muscle dystrophy

.Attributes Medicine, Published online: 09 Oct 2024 doi:10.1038/ s41591-024-03316-9Delandistrogene moxeparvovec obtained FDA approval after a bad trial, which highlights the many intricacies and obstacles of medicine growth within this setting.

Articles You Can Be Interested In

• Charity
• Pharmaceuticals
• Credit
• Logistics
• US Politics
• Savings
• Customer Service
• Supply Chain
• Local News
• Space Exploration
• Gardening
• Sales
• Motivation
• Psychology
• Savings
• Literature
• Debt Management
• World Sports
• Budgeting
• Personal Finance